NASDAQ$NEO
NeoGenomics Inc. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
NeoGenomics reported a slight revenue increase, but experienced a net loss due to increased operating expenses and amortization of acquired technology.
NeoGenomics reported a 1% increase in consolidated revenue to $117 million for Q1 2022. Clinical Services revenue increased by 2%, while Pharma Services revenue decreased by 4%. The company experienced a net loss of $49 million, compared to a net loss of $22 million in the same period last year, due to increased operating expenses and amortization of acquired technology.
- Consolidated revenue increased 1% to $117 million.
- Clinical Services revenue increased 2% to $99 million.
- Pharma Services revenue decreased 4% to $18 million.
- Net loss for the quarter was $49 million.
Headline financials
Revenue & EPS history
NeoGenomics · Revenue · Quarterly
$117M
Forward guidance
The company is focused on improving operating performance and returning to profitable growth.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+2.1%
Avg return
Earnings day
+3.4%
Avg return
5 days after
+2.7%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+28.1%
Q3 2013
Best reaction
-34.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +9.6% | +18.4% | |
| Q4 2025 | +0.5% | -13.1% | -28.1% | |
| Q3 2025 | -2.5% | -3.8% | +19.4% | |
| Q1 2025 | -34.0% | -22.8% | -26.1% | |
| Q4 2024 | -13.9% | -23.0% | -31.1% | |
| Q3 2024 | +9.3% | +11.5% | +21.6% | |
| Q2 2024 | +16.1% | +15.4% | +9.7% | |
| Q1 2024 | -8.3% | +0.5% | -8.0% | |
| Q4 2023 | +14.8% | +16.9% | +7.5% | |
| Q3 2023 | +9.6% | +3.2% | +19.1% | |
| Q2 2023 | -6.2% | -11.0% | -11.3% | |
| Q1 2023 | +19.2% | +26.4% | +13.9% | |
| Q4 2022 | +18.2% | +26.2% | +26.4% | |
| Q3 2022 | +23.1% | +58.5% | +70.0% | |
| Q2 2022 | +16.1% | +23.4% | +3.6% | |
| Q1 2022 | -10.1% | -10.1% | -18.1% | |
| Q4 2021 | +11.2% | +14.4% | -6.0% | |
| Q3 2021 | -11.1% | -6.7% | -34.5% | |
| Q2 2021 | -4.6% | -12.7% | +7.7% | |
| Q1 2021 | -11.6% | -19.5% | -14.0% | |
| Q4 2020 | -4.0% | +0.3% | -12.5% | |
| Q3 2020 | -5.0% | -6.5% | +9.0% | |
| Q2 2020 | +1.9% | +3.8% | +2.4% | |
| Q1 2020 | +2.4% | -14.1% | -8.7% | |
| Q4 2019 | -5.5% | -0.2% | -14.3% | |
| Q3 2019 | +11.3% | +8.7% | +23.7% | |
| Q2 2019 | +0.3% | +4.6% | +2.0% | |
| Q1 2019 | +2.9% | +11.3% | +2.4% | |
| Q4 2018 | +4.6% | +7.6% | +12.5% | |
| Q3 2018 | +15.0% | +12.1% | +3.7% | |
| Q2 2018 | -1.6% | -1.5% | -1.9% | |
| Q1 2018 | +5.2% | +7.0% | +21.1% | |
| Q4 2017 | +12.1% | +15.8% | +9.9% | |
| Q3 2017 | +4.2% | +3.2% | +12.2% | |
| Q2 2017 | +2.5% | +2.5% | +3.5% | |
| Q1 2017 | -11.6% | -12.2% | -13.3% | |
| Q4 2016 | +1.6% | +3.4% | -3.2% | |
| Q3 2016 | +11.6% | +10.1% | +29.4% | |
| Q2 2016 | -1.5% | -5.7% | -14.4% | |
| Q1 2016 | +5.8% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +0.7% | — | — | |
| Q2 2015 | -4.6% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.5% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +24.2% | — | — | |
| Q1 2014 | +8.9% | — | — | |
| Q4 2013 | -10.6% | — | — | |
| Q3 2013 | +28.1% | — | — | |
| Q2 2013 | -3.5% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | -10.9% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.5% | — | — | |
| Q1 2011 | -0.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q4 2010 | -3.7% | — | — | |
| Q3 2010 | +9.1% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro